LabCorp's VistaSeq

Laboratory Corporation of America announced the availability of its 27-gene VistaSeq panel that doctors can use to identify patients with a heightened risk for hereditary cancers.

LabCorp will market VistaSeq as a prognostic test for gauging increased risk of breast, ovarian, pancreatic, colorectal, endometrial, gastric, and prostate cancers, as well as melanoma. The diagnostic, performed by LabCorp specialty testing group Integrated Genetics, is intended to be used in conjunction with a person's medical and family history for cancer.

According to the firm, VistaSeq is available nationwide through any LabCorp account. Doctors and patients will also have access to additional services through LabCorp, such as insurance pre-authorization support and genetic counseling.